GlassScriptPhysician profile
Bobbi R Morrison
NPI 1285934968
$1,484.41
in general payments reported to CMS, 2019-2025
16 companies · $56.11 in 2025
The $56.11 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $747 · 2022: $232 · 2023: $257 · 2024: $192 · 2025: $56.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $319.31 | 2021 | |
| Abbvie INC. | $301.34 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $282.50 | 2021-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $136.07 | 2023-2024 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $110.04 | 2022-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $67.54 | 2021-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Axsome Therapeutics, INC. | $38.58 | 2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $38.50 | 2021 | |
| Lundbeck LLC | $36.91 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $25.11 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.88 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $16.36 | 2024 | Fanapt |
| Exact Sciences Corporation | $14.64 | 2025 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $13.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobbi Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.